Skip to main content
Wiley Open Access Collection logoLink to Wiley Open Access Collection
. 2021 Jun 26;27(45):11574–11579. doi: 10.1002/chem.202101863

Total Synthesis of (+)‐Erogorgiaene and the Pseudopterosin A−F Aglycone via Enantioselective Cobalt‐Catalyzed Hydrovinylation

Sohajl Movahhed 1,+, Julia Westphal 1,+, Alexander Kempa 2, Christian Eric Schumacher 1, Julia Sperlich 2, Jörg‐Martin Neudörfl 1, Nicole Teusch 2, Matthias Hochgürtel 2, Hans‐Günther Schmalz 1,
PMCID: PMC8456859  PMID: 34096655

Abstract

Due to their pronounced bioactivity and limited availability from natural resources, metabolites of the soft coral Pseudopterogorgia elisabethae, such as erogorgiaene and the pseudopterosines, represent important target molecules for chemical synthesis. We have now developed a particularly short and efficient route towards these marine diterpenes exploiting an operationally convenient enantioselective cobalt‐catalyzed hydrovinylation as the chirogenic step. Other noteworthy C−C bond forming transformations include diastereoselective Lewis acid‐mediated cyclizations, a Suzuki coupling and a carbonyl ene reaction. Starting from 4‐methyl‐styrene the anti‐tubercular agent (+)‐erogorgiaene (>98 % ee) was prepared in only 7 steps with 46 % overall yield. In addition, the synthesis of the pseudopterosin A aglycone was achieved in 12 steps with 30 % overall yield and, surprisingly, was found to exhibit a similar anti‐inflammatory activity (inhibition of LPS‐induced NF‐κB activation) as a natural mixture of pseudopterosins A−D or iso‐pseudopterosin A, prepared by β‐D‐xylosylation of the synthetic aglycone.

Keywords: cationic cyclization, cobalt catalysis, diterpenes, glycosides, hydrovinylation, marine natural products


Applied metal catalysis: Exploiting a practical protocol for the asymmetric hydrovinylation of stryrenes in the opening move, the stereoselective total synthesis of bioactive constituents of the soft coral pseudopterogorgia elisabethae was efficiently achieved in sequence of metal‐mediated steps to provide sufficient material for further biological investigations.

graphic file with name CHEM-27-11574-g003.jpg


Marine organisms in general and the soft coral Pseudptero‐gorgia elisabethae in particular represent a rich source of bioactive natural products, some of which are of high pharmaceutical interest.[1] Prominent examples are (+)‐erogorgiaene (1)[2] and the pseudopterosins[3] (e. g. 2, 3 and 4), the latter being biosynthetically derived from 1.[4] While 1 shows promising activity against Mycobacterium tuberculosis H37Rv,[2] the pseudopterosins have received outstanding scientific and even commercial[1a, 5] attention due to their strong anti‐inflammatory and analgesic properties.[3a, 3b, 3c, 3d, 6] More recently, the unique bioactivity of the pseudopterosins was attributed to their ability to block the NFκB pathway through activation of the glucocorticoid receptor.[7] Moreover, these compounds also reveal interesting cytotoxic and antibacterial properties,[8] and pseudopterosin A (3) was identified as a potent broad‐spectrum antibiotic agent against different pathogenic strains[9] The same compound (3) was also shown to protect synaptic function and to exhibit neuromodulatory properties while being well distributed within mammalian tissues.[10]

Due to their promising biological activity and the scarcity of material from natural sources, both erogorgiaene (1) and the pseudopterosins represent relevant target molecules for chemical synthesis. Actually, total synthesis currently appears to be the most sustainable way to provide substantial amounts of these compounds for possible pharmaceutical development. Accordingly, several research groups have elaborated synthetic routes towards erogorgiaene,[11] the pseudopterosins[12] and other structurally related marine diterpenes.[13] However, a careful analysis of the reported syntheses reveals that most (if not all) of the known approaches do not reach the required levels of overall efficiency (number of steps, yield, and stereoselectivity). We here disclose a particular short and efficient access to both (+)‐erogorgiaene (1) and the pseudopterosin A−F aglycone following a general strategy which exploits an enantioselective Co‐catalyzed hydrovinylation[14, 15] as chirogenic step ‐ in combination with diastereoselective cationic cyclization steps.

Our strategy, sketched in Scheme 1, is based on the consideration that ring C of the tricyclic pseudopterosins can be formed by a late (“biomimetic”)[4] cationic cyclization. Thus, all target molecules shown in Figure 1 can retrosynthetically be traced back to precursors of type 5, which in turn should be accessible from calamenenes of type 6 through diastereoselective double bond functionalization. In a previous study we had already shown that compound 6b can be obtained from 7b by trans‐selective Lewis acid‐catalyzed cyclization under proton‐free conditions.[16] However, our original method for the preparation of 7b (by enantioselective hydroboration of 9b followed by double Matteson homologation and Suzuki coupling) turned out to be little attractive from an operational point of view and difficult to be scaled up.[16] Therefore, we sought to apply our operationally convenient protocol for the asymmetric cobalt‐catalyzed hydrovinylation[14] to enantioselectively convert the vinyl‐arenes 9a and 9b into the chiral olefins 8a and 8b, respectively. Intermediates of type 7 should then be accessible in a single step by hydroboration of 8 and subsequent Suzuki cross‐coupling.[17]

Scheme 1.

Scheme 1

A general strategy towards marine diterpenoids related to erogorgiaene and the pseudopterosins.

Figure 1.

Figure 1

Structure of (+)‐erogorgiane (1) and selected members of the pseudopterosin family of marine diterpene gylcosides.

Following this plan, we first investigated the hydrovinylation of 9a employing chiral ligands L1 and L2, which had given the best results with other substrates in our previous study.[14] In addition, we tested the more electron‐rich new ligand L3, which differs from L1 by a methoxy group at the ligand backbone.[18]

The air‐stable pre‐catalysts (L*CoCl2) were prepared by stirring CoCl2 and the respective chiral ligand in THF for 16 h at room temperature. After solvent removal and re‐dissolution in dichloromethane the mixture was cooled to the specified temperature under an atmosphere of ethylene (1.2 bar) before substrate 9a and Et2AlCl (as an activator) were injected. As Table 1 shows, the reactions proceeded smoothly at −40 °C within 2–3 h to give the (R)‐configurated product (R)‐8a in high yield (entries 1–3).[19] While L1 and L2 behaved similarly (89 % ee), the methoxy‐substituted ligand L3 [18] proved to be even more active in this case and selectively afforded 8a with 93 % ee. By lowering the temperature to −60 °C the enantioselectivity could be further improved (entry 4). Under optimized conditions (using only 0.03 mol% of the entL3‐based catalyst at −65 °C) the reaction could be reliably performed on a multi‐gram scale (5 g) to afford the desired (S)‐configurated product (S)‐8a in almost quantitative isolated yield and 98–99 % enantiomeric excess.[20]

Table 1.

Behavior of different ligands and temperature effects in the cobalt‐catalyzed enantioselective hydrovinylation of 4‐methylstyrene (9a).

graphic file with name CHEM-27-11574-g008.jpg

Entry

L*

Temp. [°C]

8a [a] [%]

ee[b] [%]

abs. config.[c]

1

L1 (1 mol %)

−40

100

89

R

2

L2 (1 mol %)

−40

97

89

R

3

L3 (1 mol %)

−40

100

93

R

4

L3 (1 mol %)

−60

100

97

R

5

L3 (1 mol %)

−78

0

6

ent‐L3 (0.03 mol %)

−65

98[d]

98‐99[e]

S

Reaction conditions: 9a (1.0 eq), CH2Cl2, ethylene (1.2 bar), Co(L*)Cl2, Et2AlCl (Co : Al=1 : 6). [a] GC yield of 8a as determined by FID‐GCMS; [b] Determined by FID‐GC on a chiral stationary phase; [c] Determined by comparison of the optical rotatory values with those given in Ref. [19]. [d] Isolated yield (gram scale); [e] The reaction was performed several times to reproducibly afford (S)‐8a with 98–99 % ee.

According to the chosen strategy, the next task was the elongation of the side chain to convert (S)‐8a into the allylic acetate 7a (Scheme 2). For this purpose, (S)‐8a was first hydroborated with 9‐BBN and the in situ formed intermediate 10a was directly coupled under Suzuki conditions with the vinyl iodide 12 to give 7a in high yield. Building block 12 was prepared from propargylic alcohol (11) through Zr‐catalyzed methyl alumination/iodination[21] followed by acetylation of the alcohol function according to a previously described protocol.[13h, 17]

Scheme 2.

Scheme 2

Total synthesis of (+)‐erogorgiaene (1). Reagents and conditions: (a) 9‐BBN, THF, r.t., 6 h; (b) Me3Al, Cp2ZrCl2 (25 mol%), CH2Cl2, then I2, THF, 0 °C→rt; (c) NEt3, cat. DMAP, Ac2O, CH2Cl2, 0 °C→r.t.; (d) addition of 10a in THF to a suspension of 12, Cs2CO3 and Pd(PPh3)4 (5 mol%) in DMF, H2O, 40 °C, 18 h; (e) Me2AlCl, CH2Cl2, −78 °C, 6 h; (f) (CH2O)n, Et2AlCl, CH2Cl2, −70 °C, 1.5 h; separation of diastereomers by preparative HPLC; (g) Pfaltz catalyst 14 (2 mol%), H2 (35 bar), CH2Cl2, r.t., 2 d; separation of diastereomers by column chromatography; (h) I2, PPh3, imidazole, CH2Cl2, r.t., 30 min; (i) isocrotyl‐lithium, THF, −78 °C→r.t., 18 h. 9‐BBN=9‐borabicyclo[3.3.1]‐nonane; DMAP=4‐N,N‐dimethylaminopyridin.

After screening several reaction conditions (see Table SI‐1) we found that the Lewis acid‐mediated cyclization of nuciferyl acetate (7a) was best performed by treating a solution of 7a in dichloromethane at −78 °C with Me2AlCl. This way, the trans‐calamenene 6a was obtained in high yield and good diastereoselectivity (87 : 13 d.r.). After elongation of the side chain by means of a carbonyl Alder‐ene reaction (using paraformaldehyde in the presence of Et2AlCl)[22] the diastereomers could be separated by preparative HPLC to give the stereochemically pure alcohol 13a in 86 % isolated yield. Introduction of the side chain stereocenter was then achieved by diastereoselective hydrogenation of 13a using the Ir‐catalyst 14 developed by Pfaltz and coworkers.[23] The crude product (containing 4 % of the undesired diastereomer) could be readily purified through flash chromatography to afford pure 15a in 94 % yield. With this compound in hand, the synthesis of the target molecule 1 was then efficiently concluded in only two steps, i. e. by iodination of the alcohol function (I2, PPh3, imidazole) and coupling of the resulting iodide 16 with isocrotyl‐lithium.[11a, 24] This way, (+)‐erogorgiaene (1) was obtained in 46 % overall yield over seven steps starting from commercial 4‐methylstyrene (9a). At this point, the configurational assignments were confirmed by careful comparison of the NMR data with those reported by Aggarwal, who had prepared all four diastereomers of 1.[11d] In addition, the optical rotation of our synthetic sample ([α]D=+22°; c=0.18) matched the reported value for the natural product.[2a]

Following the same general strategy (Scheme 1), we next tackled the synthesis of the pseudopterosin A−F aglycone (20) as a second target molecule in this study (Scheme 3). Starting from the styrene derivative 9b, which is available from veratrole in three steps,[16] the first task was to achieve the Co‐catalyzed hydrovinylation to 8b.[25] According to our previous experience, this proved to be more challenging (as compared to the hydrovinylation of 8a) due to the additional methoxy‐substituent in ortho‐position to the vinyl group.[14, 26] However, after careful optimization of the conditions (Table SI‐2) the desired transformation could be successfully performed on a gram scale (2.7 g) using a L2‐derived catalyst to afford the alkene 8b (84 % ee) in 87 % isolated yield (after distillation). Noteworthy, ligand L2, prepared from (R,R)‐Taddol afforded the desired (S)‐configurated product 8b, while the same ligand gave rise to the (R)‐configurated product when substrate 9a was employed (see Table 1).[27]

Scheme 3.

Scheme 3

Total synthesis of the pseudopterosin A−F agylcone (20). Reagents and conditions: (a) ethylene (1.2 bar), Co(L2)Cl2 (5 mol%), Et2AlCl (30 mol%), CH2Cl2, −20 °C, 6 h; (b) 9‐BBN, THF, r.t., 24 h; then transfer to a suspension of 12, [Pd(dppf)Cl2] • CH2Cl2 (5 mol%), AsPh3 (5 mol%) and Cs2CO3 in H2O/DMF, then μW (50 W), 40 °C, 2 h; (c) Me2AlCl, C6F6, 5 °C, 1.5 h; (d) (CH2O)n, Et2AlCl, CH2Cl2, 20 °C, sonification, 4.5 h; separation of diastereomers by column chromatography; (e) 14 (1 mol%), H2 (20 bar), CH2Cl2, r.t., 48 h; (f) DAIB, TEMPO (20 mol%), CH2Cl2, r.t., 1 h, separation of diastereomers by column chromatography; (g) diethyl (2‐methylallyl)phosphonate, n‐BuLi, TPPA, THF, −78 °C to r.t., 6 h.; (h) AlCl3 (20 mol%), CH2Cl2, −5 °C, 4.5 h; (i) LiSEt (10 equiv), DMF, 160 °C, 3 h. dppf=1,1’‐bis(diphenylphosphino)ferrocene; TEMPO=2,2,6,6‐tetramethylpiperidin‐1‐yl‐oxyl; DAIB=(diacetoxy)iodobenzene; TPPA=tripyrrolidinophosphoric acid triamide.

The conversion of 8b into the allylic acetate 7b was achieved in 89 % yield by hydroboration (9‐BBN) and microwave‐assisted Suzuki coupling of the resulting borane intermediate with the vinyl iodide 12. The following Friedel‐Crafts‐type cyclization of 7b (under strictly aprotic conditions to avoid the undesired disproportionation of the product)[16] reproducibly afforded 6b with high yield and trans‐diastereoselectivity (d.r.=9 : 1) using Me2AlCl as a Lewis acid in hexafluorobenzene as a solvent. As in the synthesis of 1 (Scheme 2) the diastereomers were not separable at this stage. However, after elongation of the side chain by Et2AlCl‐mediated carbonyl‐ene reaction with paraformaldehyde under sonification, the isomers could be separated by flash column chromatography, and the diastereomerically pure alcohol 13b was isolated in 87 % yield. Hydrogenation of the double bond, again using the Ir‐catalyst 14, proceeded highly diastereoselectively (d.r.=94 : 6).[28] After TEMPO‐mediated oxidation of the alcohol with diacetoxyiodobenzene[29] the aldehyde 17 was obtained in 75 % yield over two steps. To complete the serrulatane skeleton, 17 was transformed with diethyl (2‐methylallyl)phosphonate[30] in a Horner‐Wadsworth‐Emmons olefination to afford the (E)‐configurated diene 18.

As the final critical step of the synthesis of the pseudopterosin A−F aglycone (20) we carefully investigated the diastereoselective cationic cyclization of 18 to the amphilectane 19. In this context we first tested various acids and Lewis acids using CH2Cl2 as a solvent (see Table S3). While most of these reagents only gave low conversions and/or selectivities, the by far best result was obtained with anhydrous aluminum chloride. Under optimized conditions the cyclization of 18 proceeded efficiently in the presence of 20 mol% of AlCl3 in CH2Cl2 at −5 °C to afford the desired product 19 in 92 % isolated yield and with high diastereoselectivity (d.r.=95 : 5).[31] The relative and absolute configuration of the cyclization product 19 was unambiguously proven by X‐ray analysis of a single crystal obtained from a melt (Figure 2).[32] The concluding cleavage of both methoxy groups then proceeded smoothly upon heating of 19 with an excess of LiSEt in DMF[12f, 33] to afford the target molecule 20 in high yield (40 % overall from 8b over 8 steps).

Figure 2.

Figure 2

Structure of 19 in the crystalline state.

While the conversion of the aglycone 20 into pseudopterosins A (3) and E (4), respectively, has been previously reported,[12a, 12b] we synthesized the new glycosidic compound iso‐pseudopterosin A (iso‐ 3) in a 6 : 1 mixture with 3 by treatment of 20 (freshly prepared from the more stable and storable precursor 19) with the D‐xylose‐derived α‐trichloroacetimidate 21 in the presence of BF3 etherate under strictly anhydrous conditions (Scheme 4).[34]

Scheme 4.

Scheme 4

Synthesis of iso‐pseudopterosin A (iso3): Reagents and conditions: a) 21, BF3 .Et2O, 4 Å MS, CH2Cl2, −78 °C, 30 min; b) K2CO3, MeOH, r.t., 18 h.

The resulting mixture of β‐xylosides (iso3/3=85 : 15) was finally assessed with respect to its ability to inhibit the NFκB pathway[7] in comparison with compounds 19 and 20 as well as a mixture of pseudopterosins A−D from natural sources as a control. We found that the synthetic iso3/3 mixture is at least as active as the mixture of pseudopterosins A−D (Figure 3). Interestingly, the aglycone 20 proved to be equally potent as the corresponding glycosides in this assay,[7] while the dimethyl ether 19 was nearly inactive.

Figure 3.

Figure 3

Anti‐inflammatory activity of natural pseudopterosins A−D (mixture) in comparison to the synthetic compounds 19, 20 (pseudopterosin A−F aglycone), and iso‐pseudopterosin A (iso3/3=6 : 1) as reflected by the inhibition of the NFκB pathway in LPS‐stimulated MDA‐MB‐231 breast cancer cells.

This result somewhat contradicts earlier reports on structure‐activity relationships of the pseudopterosins and derivatives, which had indicated the importance of the sugar unit for the anti‐inflammatory activity in mouse ear tests.[3a, 3b, 3c, 3d, 6] This indicates that a major function of the glycoside moiety may be to protect the sensitive catechol moiety of the aglycone from oxidation, besides improving the water solubility of the natural product.

In summary, we have developed a powerful, general strategy for the stereoselective total synthesis of the marine natural products erogorgiaene and the pseudopterosins. In the chirogenic opening step, we exploited a Co‐catalyzed enantioselective hydrovinylation, thus demonstrating the practicality of this methodology in the context of total synthesis. The synthetic sequences, mainly based on metal‐catalyzed or ‐mediated transformations, also feature highly selective cationic cyclizations and the diastereoselective elaboration of the serrulatane side chain by substrate‐controlled Pfaltz hydrogenation of the carbonyl‐ene products 15a and 15b, respectively. Both target molecules were obtained in less than 10 steps with high overall yield. The efficient access to the pseudopterosin aglycone (20) enabled us to also prepare iso‐pseudopterosin A, a novel anti‐inflammatory compound, which proved to be equally active as a mixture of natural pseudopterosins in the inhibition of the NFκB pathway. Thus, we are optimistic that this work will stimulate research into the pharmaceutical exploitation of pseudopterosins and related natural products in the future ‐ without the need to harvest the corals.

Conflict of interest

The authors declare no conflict of interest.

Supporting information

As a service to our authors and readers, this journal provides supporting information supplied by the authors. Such materials are peer reviewed and may be re‐organized for online delivery, but are not copy‐edited or typeset. Technical support issues arising from supporting information (other than missing files) should be addressed to the authors.

Supporting Information

Acknowledgements

This work was supported by the Fonds der Chemischen Industrie (doctoral fellowship to J.W.) and the University of Cologne. We gratefully thank Prof. R. G. Kerr for providing a sample of a pseudopterosin A−D mixture from natural sources. Open access funding enabled and organized by Projekt DEAL.

S. Movahhed, J. Westphal, A. Kempa, C. E. Schumacher, J. Sperlich, J.-M. Neudörfl, N. Teusch, M. Hochgürtel, H.-G. Schmalz, Chem. Eur. J. 2021, 27, 11574.

Dedicated to Martin F. Semmelhack on the occasion of his approaching 80th birthday.

References

  • 1. 
  • 1a.Heckrodt T., Mulzer J., Natural Products Synthesis II, Vol. 244, Springer, 2005, pp. 1–41; [Google Scholar]
  • 1b.Marrero J., Rodríguez I. I., Rodríguez A. D., in Comprehensive Natural Products II, Elsevier, 2010, pp. 363–428; [Google Scholar]
  • 1c.Berrue F., McCulloch M. W., Kerr R. G., Bioorg. Med. Chem. 2011, 19, 6702–6719. [DOI] [PubMed] [Google Scholar]
  • 2. 
  • 2a.Rodríguez A. D., Ramírez C., J. Nat. Prod. 2001, 64, 100–102; for the isolation of the enantiomeric compound ent- 1 from a different organism, see: [DOI] [PubMed] [Google Scholar]
  • 2b.Kolesnikova S. A., Kalinovsky A. I., Fedorov S. N., Shubina L. K., Stonik V. A., Phytochemistry 2006, 67, 2115–2119. [DOI] [PubMed] [Google Scholar]
  • 3. 
  • 3a.Look S. A., Fenical W., Jacobs R. S., Clardy J., Proc. Natl. Acad. Sci. USA 1986, 83, 6238–6240; [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3b.Look S. A., Fenical W., Matsumoto G. K., Clardy J., J. Org. Chem. 1986, 51, 5140–5145; [Google Scholar]
  • 3c.Look S. A., Fenical W., Tetrahedron 1987, 43, 3363–3370; [Google Scholar]
  • 3d.Roussis V., Wu Z., Fenical W., Strobel S. A., Van Duyne G. D., Clardy J., J. Org. Chem. 1990, 55, 4916–4922; [Google Scholar]
  • 3e.Rodríguez I. I., Shi Y.-P. P., García O. J., Rodríguez A. D., Mayer A. M., Sánchez J. A., Ortega-Barria E., González J., J. Nat. Prod. 2004, 67, 1672–1680. [DOI] [PubMed] [Google Scholar]
  • 4. 
  • 4a.Coleman A. C., Kerr R. G., Tetrahedron 2000, 56, 9569–9574; [Google Scholar]
  • 4b.Kohl A. C., Kerr R. G., Mar. Drugs 2003, 1, 54–65; [Google Scholar]
  • 4c.Mydlarz L. D., Jacobs R. S., Boehnlein J., Kerr R. G., Chem. Biol. 2003, 10, 1051–1056; [DOI] [PubMed] [Google Scholar]
  • 4d.Ferns T. A., Kerr R. G., J. Org. Chem. 2005, 70, 6152–6157; [DOI] [PubMed] [Google Scholar]
  • 4e.Ferns T., Kerr R. G., Tetrahedron 2005, 61, 12358–12365; [Google Scholar]
  • 4f.Kerr R. G., Kohl A. C., Ferns T. A., J. Ind. Microbiol. Biotechnol. 2006, 33, 532–538; [DOI] [PubMed] [Google Scholar]
  • 4g.Berrue F., Kerr R. G., Nat. Prod. Rep. 2009, 26, 681–710. [DOI] [PubMed] [Google Scholar]
  • 5. 
  • 5a.Rouhi A. M., Chem. Eng. News 1995, 73, 42–44; [Google Scholar]
  • 5b.Kijjoa A., Sawangwong P., Mar. Drugs 2004, 2, 73–82; [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5c.Newman D. J., Cragg G. M., J. Nat. Prod. 2004, 67, 1216–1238 [DOI] [PubMed] [Google Scholar]
  • 5d.Mayer A. M. S., Glaser K. B., Cuevas C., Jacobs R. S., Kem W., Little R. D., McIntosh J. M., Newman D. J., Potts B. C., Shuster D. E., Trends Pharmacol. Sci. 2010, 31, 255–265. [DOI] [PubMed] [Google Scholar]
  • 6. 
  • 6a.Mayer A. M. S., Jacobson P. B., Fenical W., Jacobs R. S., Glaser K. B., Life Sci. 1998, 62, PL401-PL407; [DOI] [PubMed] [Google Scholar]
  • 6b.Ata A., Kerr R. G., Moya C. E., Jacobs R. S., Tetrahedron 2003, 59, 4215–4222; [Google Scholar]
  • 6c.Hoarau C., Day D., Moya C., Wu G., Hackim A., Jacobs R. S., Little R. D., Tetrahedron Lett. 2008, 49, 4604–4606; [Google Scholar]
  • 6d.Correa H., Valenzuela A. L., Ospina L. F., Duque C., J. Inflammation 2009, 6, 5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Sperlich J., Kerr R., Teusch N., Mar. Drugs 2017, 15, 262. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8. 
  • 8a.Correa H., Aristizabal F., Duque C., Kerr R., Mar. Drugs 2011, 9, 334–343; [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8b.McCulloch M. W., Haltli B., Marchbank D. H., Kerr R. G., Mar. Drugs 2012, 10, 1711–1728. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9. 
  • 9a.Ata A., Win H. Y., Holt D., Holloway P., Segstro E. P., Jayatilake G. S., Helv. Chim. Acta 2004, 87, 1090–1098; [Google Scholar]
  • 9b.Xiong M., Guo Z., Han B., Chen M., Nat. Prod. Res. 2015, 29, 1624–1629. [DOI] [PubMed] [Google Scholar]
  • 10. 
  • 10a.Caplan S. L., Zheng B., Dawson-Scully K., White C. A., West L. M., Mar. Drugs 2016, 14, 55–68; [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10b.Niu X., Yu C., Jiang G., Wu J., Tan X., Zhang W., Hou L., Folia Neuropathol. 2018, 56, 104–111. [DOI] [PubMed] [Google Scholar]
  • 11. 
  • 11a.Cesati R. R., de Armas J., Hoveyda A. H., J. Am. Chem. Soc. 2004, 126, 96–101; [DOI] [PubMed] [Google Scholar]
  • 11b.Davies H. M. L., Walji A. M., Angew. Chem. Int. Ed. 2005, 44, 1733–1735; [DOI] [PubMed] [Google Scholar]; Angew. Chem. 2005, 117, 1761–1735; [Google Scholar]
  • 11c.Yadav J. S., Basak A. K., Srihari P., Tetrahedron Lett. 2007, 48, 2841–2843; [Google Scholar]
  • 11d.Elford T. G., Nave S., Sonawane R. P., Aggarwal V. K., J. Am. Chem. Soc. 2011, 133, 16798–16801; [DOI] [PubMed] [Google Scholar]
  • 11e.Yu X., Su F., Liu C., Yuan H., Zhao S., Zhou Z., Quan T., Luo T., J. Am. Chem. Soc. 2016, 138, 6261–6270; [DOI] [PubMed] [Google Scholar]
  • 11f.Incerti-Pradillos C. A., Kabeshov M. A., O'Hora P. S., Shipilovskikh S. A., Rubtsov A. E., Drobkova V. A., Balandina S. Y., Malkov A. V., Chem. Eur. J. 2016, 22, 14390–14396. [DOI] [PubMed] [Google Scholar]
  • 12. 
  • 12a.Broka C. A., Chan S., Peterson B., J. Org. Chem. 1988, 53, 1584–1586; [Google Scholar]
  • 12b.Corey E. J., Carpino P., J. Am. Chem. Soc. 1989, 111, 5472–5474; [Google Scholar]
  • 12c.Corey E. J., Carpino P., Tetrahedron Lett. 1990, 31, 3857–3858; [Google Scholar]
  • 12d.Ganguly A. K., Mccombie S. W., Cox B., Lin S., Mcphail A. T., Pure Appl. Chem. 1990, 62, 1289–1291; [Google Scholar]
  • 12e.Buszek K. R., Bixby D. L., Tetrahedron Lett. 1995, 36, 9129–9132; [Google Scholar]
  • 12f.Majdalani A., Schmalz H.-G., Synlett 1997, 11, 1303–1305; [Google Scholar]
  • 12g.Corey E. J., Lazerwith S. E., J. Am. Chem. Soc. 1998, 120, 12777–12782; [Google Scholar]
  • 12h.Lazerwith S. E., Johnson T. W., Corey E. J., Org. Lett. 2000, 2, 2389–2392; [DOI] [PubMed] [Google Scholar]
  • 12i.Chow R., Kocienski P. J., Kuhl A., LeBrazidec J.-Y., Muir K., Fish P., J. Chem. Soc. Perkin Trans. 1 2001, 2344–2355; [Google Scholar]
  • 12j.Harrowven D. C., Tyte M. J., Tetrahedron Lett. 2004, 45, 2089–2091; [Google Scholar]
  • 12k.Mans D. J., Cox G. A., RajanBabu T. V., J. Am. Chem. Soc. 2011, 133, 5776–5779; [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12l.Kocieński P., Cooksey J., Schmidt A., Snaddon T., Kilner C., Synthesis 2012, 44, 2779–2785; [Google Scholar]
  • 12m.Newton C. G., Drew S. L., Lawrence A. L., Willis A. C., Paddon-Row M. N., Sherburn M. S., Nat. Chem. 2015, 7, 82–86; [DOI] [PubMed] [Google Scholar]
  • 12n.Newton C. G., Sherburn M. S., Nat. Prod. Rep. 2015, 32, 865–876; [DOI] [PubMed] [Google Scholar]
  • 12o.Tenneti S., Biswas S., Cox G. A., Mans D. J., Lim H. J., RajanBabu T. V., J. Am. Chem. Soc. 2018, 140, 9868–9881. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13. 
  • 13a.Geller T., Jakupovic J., Schmalz H.-G., Tetrahedron Lett. 1998, 39, 1541–1544; [Google Scholar]
  • 13b.Geller T., Schmalz H.-G., Bats J. W., Tetrahedron Lett. 1998, 39, 1537–1540; [Google Scholar]
  • 13c.Dehmel F., Schmalz H.-G., Org. Lett. 2001, 3, 3579–3582; [DOI] [PubMed] [Google Scholar]
  • 13d.Davidson J. P., Corey E. J., J. Am. Chem. Soc. 2003, 125, 13486–13489; [DOI] [PubMed] [Google Scholar]
  • 13e.Harmata M., Hong X., Org. Lett. 2005, 7, 3581–3583; [DOI] [PubMed] [Google Scholar]
  • 13f.Flachsmann F., Schellhaas K., Moya C. E., Jacobs R. S., Fenical W., Bioorg. Med. Chem. 2010, 18, 8324–8333; [DOI] [PubMed] [Google Scholar]
  • 13g.McCulloch M. W. B., Berrue F., Haltli B., Kerr R. G., J. Nat. Prod. 2011, 74, 2250–2256; [DOI] [PubMed] [Google Scholar]
  • 13h.Lölsberg W., Werle S., Neudörfl J.-M., Schmalz H.-G., Org. Lett. 2012, 14, 5996–5999; [DOI] [PubMed] [Google Scholar]
  • 13i.Yang M., Yang X., Sun H., Li A., Angew. Chem. Int. Ed. 2016, 55, 2851–2855; [DOI] [PubMed] [Google Scholar]; Angew. Chem. 2016, 128, 2901–2855; [Google Scholar]
  • 13j.Zhang X., Fang X., Xu M., Lei Y., Wu Z., Hu X., Angew. Chem. Int. Ed. 2019, 58, 7845–7849; [DOI] [PubMed] [Google Scholar]; Angew. Chem. 2019, 131, 7927–7849. [Google Scholar]
  • 14.Movahhed S., Westphal J., Dindaroǧlu M., Falk A., Schmalz H. G., Chem. Eur. J. 2016, 22, 7381–7384. [DOI] [PubMed] [Google Scholar]
  • 15.For the well-investigated asymmetric hydrovinylation of styrenes using (highly sensitive) Ni catalysts, see, for instance:
  • 15a.Wilke G., Angew. Chem. Int. Ed. 1988, 27, 185–206; [Google Scholar]; Angew. Chem. 1988, 100, 189–211; [Google Scholar]
  • 15b.RajanBabu T. V., Synlett 2009, 2009, 853–885; [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15c.Lassauque N., Franciò G., Leitner W., Adv. Synth. Catal. 2009, 351, 3133–3138; [Google Scholar]
  • 15d.for earlier reports on cobalt-catalyzed hydrovinylation, see
  • 15e.Grutters M. M. P., Müller C., Vogt D., J. Am. Chem. Soc. 2006, 128, 7414–7415; [DOI] [PubMed] [Google Scholar]
  • 15f.Grutters M. M. P., van der Vlugt J. I., Pei Y., Mills A. M., Lutz M., Spek A. L., Müller C., Moberg C., Vogt D., Adv. Synth. Catal. 2009, 351, 2199–2208; for selected reviews, see: [Google Scholar]
  • 15g.Hilt G., Eur. J. Org. Chem. 2012, 2012, 4441–4451; [Google Scholar]
  • 15h.RajanBabu T. V., Adam Cox G., Lim H. J., Nomura N., Sharma R. K., Smith C. R., Zhang A., Comprehensive Organic Synthesis , 2nd ed., G. A. Molander, P. Knochel (eds.), Vol. 5, Oxford: Elsevier, 2014, pp. 1582–1620. [Google Scholar]
  • 16.Werle S., Fey T., Neudörfl J. M., Schmalz H.-G., Org. Lett. 2007, 9, 3555–3558. [DOI] [PubMed] [Google Scholar]
  • 17. 
  • 17a.Miyaura N., Ishiyama T., Sasaki H., Ishikawa M., Satoh M., Suzuki A., J. Am. Chem. Soc. 1989, 111, 314–321; [Google Scholar]
  • 17b.Meng D., Bertinato P., Balog A., Su D.-S., Kamenecka T., Sorensen E. J., Danishefsky S. J., J. Am. Chem. Soc. 1997, 119, 10073–10092. [Google Scholar]
  • 18.For the preparation of ligands L1-L3 see:
  • 18a.Velder J., Robert T., Weidner I., Neudörfl J. M., Lex J., Schmalz H. G., Adv. Synth. Catal. 2008, 350, 1309–1315; [Google Scholar]
  • 18b.Dindaroǧlu M., Falk A., Schmalz H. G., Synthesis 2013, 45, 527–535. [Google Scholar]
  • 19.The absolute configuration of 8a was assigned by comparison of the optical rotatory values with those given by: Zhang A., RajanBabu T. V., Org. Lett. 2004, 6, 1515–1517.15101781 [Google Scholar]
  • 20.The enantiomeric excess of 8a was determined by GC analysis on a MEGA-DEX B-SE column.
  • 21. 
  • 21a.Van Horn D. E., Negishi E., J. Am. Chem. Soc. 1978, 100, 2252–2254; [Google Scholar]
  • 21b.Wipf P., Lim S., Angew. Chem. Int. Ed. Engl. 1993, 32, 1068–1071; [Google Scholar]; Angew. Chem. 1993, 105, 1095–1071. [Google Scholar]
  • 22. 
  • 22a.Alder K., Söll H., Söll H., Justus Liebigs Ann. Chem. 1949, 565, 73–99; [Google Scholar]
  • 22b.Snider B. B., Ron E., J. Am. Chem. Soc. 1985, 107, 8160–8164. [Google Scholar]
  • 23. 
  • 23a.Pfaltz A., Blankenstein J., Hilgraf R., Hörmann E., McIntyre S., Menges F., Schönleber M., Smidt S. P., Wüstenberg B., Zimmermann N., Adv. Synth. Catal. 2003, 345, 33–43; [Google Scholar]
  • 23b.Bell S., Wüstenberg B., Kaiser S., Menges F., Netscher T., Pfaltz A., Science 2006, 311, 642–644. [DOI] [PubMed] [Google Scholar]
  • 24.Meyers A. I., Stoianova D., J. Org. Chem. 1997, 62, 5219–5221. [Google Scholar]
  • 25.The hydrovinylation of 9b was reported by RajanBabu (ref. [12 l] and [12p]) to proceed with high yield and >95 %ee in the presence of a Ni-phosphoramidate catalyst. However, we did not succeed in reproducing this result under our conditions, probably due to the extreme sensitivity of the Ni-based catalyst and our inability to perform the reaction in a glovebox.
  • 26.Westphal J., Schumacher C. E., Schmalz H.-G., Synthesis 2017, 49, 218–224. [Google Scholar]
  • 27.The absolute configuration of 8b was assigned by comparison of the optical rotatory values with those given in refs. [12l] and [16].
  • 28.Noteworthy, the diastereoselectivity was virtually the same when the enantiomeric Ir-catalyst (ent-14) was employed in the hydrogenation of 13b. The absence of a matched/mismatched effect indicates a remarkable level of substrate control in this reaction. The use of Pd/C, Wilkinson's catalyst, RuCl2((R)-BINAP) or Crabtree's catalyst only gave low diastereoselectivity or no conversion at all.
  • 29.De Mico A., Margarita R., Parlanti L., Vescovi A., Piancatelli G., J. Org. Chem. 1997, 62, 6974–6977. [Google Scholar]
  • 30. 
  • 30a.Wang Y., West F. G., Synthesis 2002, 33, 99–103; [Google Scholar]
  • 30b.Fourgeaud P., Midrier C., Vors J.-P., Volle J.-N., Pirat J.-L., Virieux D., Tetrahedron 2010, 66, 758–764. [Google Scholar]
  • 31.The fact that the diastereoselectivity of the cyclization of 18 strongly depends on the nature of the catalyst suggests that different mechanistic pathways might be involved. We cannot exclude that AlCl3 (or FeCl3) in CH2Cl2 acts as a SET oxidation agent in this case, see: H. Bock, W. Kaim, Acc. Chem. Res. 1982, 15, 9–17.
  • 32.Deposition Number 1811361 contains the supplementary crystallographic data for this paper. These data are provided free of charge by the joint Cambridge Crystallographic Data Centre and Fachinformationszentrum Karlsruhe Access Structures service www.ccdc.cam.ac.uk/structures.
  • 33.Cvengroš J., Neufeind S., Becker A., Schmalz H.-G., Synlett 2008, 1993–1998. [Google Scholar]
  • 34. 
  • 34a.Pletcher J. M., McDonald F. E., Org. Lett. 2005, 7, 4749–4752; [DOI] [PubMed] [Google Scholar]
  • 34b.Tanis V. M., Moya C., Jacobs R. S., Little R. D., Tetrahedron 2008, 64, 10649–10663; [Google Scholar]
  • 34c.Ori M., Ito Y., Ogawa T., Carbohydr. Res. 1990, 195, 199–224. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

As a service to our authors and readers, this journal provides supporting information supplied by the authors. Such materials are peer reviewed and may be re‐organized for online delivery, but are not copy‐edited or typeset. Technical support issues arising from supporting information (other than missing files) should be addressed to the authors.

Supporting Information


Articles from Chemistry (Weinheim an Der Bergstrasse, Germany) are provided here courtesy of Wiley

RESOURCES